Patents by Inventor Kim Vilbour Andersen

Kim Vilbour Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180344846
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: August 8, 2018
    Publication date: December 6, 2018
    Applicant: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Patent number: 10058610
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: August 28, 2018
    Assignee: Symphogen A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Publication number: 20170165365
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: November 14, 2016
    Publication date: June 15, 2017
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjaer, Thomas Tuxen Poulsen
  • Publication number: 20170000895
    Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
    Type: Application
    Filed: May 28, 2016
    Publication date: January 5, 2017
    Applicant: ARTS BIOLOGICS A/S
    Inventors: Peter Nordkild, Svend Lindenberg, Claus Yding Andersen, Kim Vilbour Andersen
  • Patent number: 9527913
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: December 27, 2016
    Assignee: SYMPHOGEN A/S
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejer Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Patent number: 9353365
    Abstract: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside of the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: May 31, 2016
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Jesper Mortensen Haaning, Kim Vilbour Andersen
  • Patent number: 9353172
    Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilization, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: May 31, 2016
    Assignee: ARTS BIOLOGICS A/S
    Inventors: Peter Nordkild, Svend Lindenberg, Claus Yding Andersen, Kim Vilbour Andersen
  • Patent number: 9272019
    Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analog thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 1, 2016
    Assignee: Novo Nordisk A/S
    Inventors: Allan Christian Shaw, Charlotte Helgstrand, Michael Paolo Bastner Sandrini, Sebastian Beck Joergensen, Henning Thoegersen, Kristian Sass-Oerum, Sven Hastrup, Kim Vilbour Andersen
  • Publication number: 20160015784
    Abstract: The invention relates to MIC-1 fusion proteins. More specifically it relates to compounds comprising fusion proteins comprising a MIC-1 protein or an analogue thereof at the C-terminus of the fusion protein and a functional variant of human serum albumin at the N-terminus of the fusion protein connected via a peptide linker. The compounds of the invention have MIC-1 activity. The invention also relates to pharmaceutical compositions comprising such compounds and pharmaceutically acceptable excipients, as well as the medical use of the compounds.
    Type: Application
    Filed: June 17, 2015
    Publication date: January 21, 2016
    Inventors: Allan Christian Shaw, Charlotte Helgstrand, Michael Paolo Bastner Sandrini, Sebastian Beck Joergensen, Henning Thoegersen, Kristian Saas-Oerum, Sven Hastrup, Kim Vilbour Andersen
  • Publication number: 20150086478
    Abstract: The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 26, 2015
    Inventors: Johan Lantto, Kim Vilbour Andersen, Peter Sejr Andersen, Magnus Strandh, Klaus Koefoed, Lars Søgaard Nielsen, Mikkel Wandahl Pedersen, Helle Jacobsen, Michael Kragh, Ida Kjær, Thomas Tuxen Poulsen
  • Patent number: 8987202
    Abstract: Gla domain variants of human Factor VII or human Factor VIIa, comprising 1-15 amino acid modifications relative to the human Factor VII or human Factor VIIa sequence shown in SEQ ID NO:1, wherein a hydrophobic amino acid residue has been introduced by substitution in position 34; or having an amino acid substitution in position 36; and use of the variants for the treatment of intracerebral haemorrhage (ICH) or trauma.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: March 24, 2015
    Assignee: Bayer Healthcare LLC
    Inventors: Jesper Mortensen Haaning, Kim Vilbour Andersen, Claus Bornaes
  • Publication number: 20140228292
    Abstract: The present invention relates to a long acting biologically active luteinizing hormone (LH) compound comprising an LH agonist linked to a pharmaceutically acceptable molecule providing an in vivo plasma half-life of the LH agonist or LH compound which is increased substantially compared to the in vivo plasma half-life of an LH agonist administered in the same manner as the LH compound. The present invention relates to methods for controlled ovarian stimulation which can be used in conjunction with assisted reproduction technologies such as in vitro fertilisation, intra cytoplasmatic sperm injection, intra uterine insemination and in vitro maturation. In other aspects the invention relates to methods for inducing folliculogenesis and methods for providing luteal support for the corpora lutea.
    Type: Application
    Filed: July 9, 2012
    Publication date: August 14, 2014
    Applicant: ARTS BIOLOGICS A/S
    Inventors: Peter Nordkild, Svend Lindenberg, Claus Yding Andersen, Kim Vilbour Andersen
  • Publication number: 20120289450
    Abstract: The present invention relates to cellulase variants, i.e., endo-beta-1,4-glucanase variants, derived from a parental cellulase, i.e., endo-beta-1,4-glucanase, by substitution, insertion and/or deletion, which variant has a catalytic core domain, in which the variant at position 5 holds an alanine residue (A), a serine residue (S), or a threonine residue (T); at position 8 holds a phenylalanine residue (F), or a tyrosine residue (Y); at position 9 holds a phenylalanine residue (F), a tryptophan residue (W), or a tyrosine residue (Y); at position 10 holds an aspartic acid residue (D); and at position 121 holds an aspartic acid residue (D).
    Type: Application
    Filed: May 15, 2012
    Publication date: November 15, 2012
    Applicant: NOVOZYMES A/S
    Inventors: Kim Vilbour Andersen, Martin Schülein, Lars Christiansen, Bo Damgaard, Claus Von der Osten
  • Publication number: 20120171765
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Application
    Filed: November 18, 2011
    Publication date: July 5, 2012
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Publication number: 20120135912
    Abstract: The invention provides novel 2D-VCAM-1 variant polypeptides and conjugates thereof that bind human VLA4. The invention also provides related polynucleotides, compositions, vectors, host cells, and methods.
    Type: Application
    Filed: May 10, 2011
    Publication date: May 31, 2012
    Applicant: PERSEID THERAPEUTICS LLC
    Inventors: MADAN M. PAIDHUNGAT, AMULYA NANISETTI, THOMAS BOUQUIN, KIM VILBOUR ANDERSEN, STEVEN J. CHAPIN, CLAUS KREBBER, RONG A. FAN, DANIEL MALASHOCK, AMY BRIDEAU-ANDERSEN, ERIK KARRER, BRUCE DEVENS, STEVEN H. BASS
  • Publication number: 20120107852
    Abstract: Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed. The methods involve a) expressing a diversified population of nucleotide sequences encoding a polypeptide of interest, b) screening the polypeptides expressed in step a) for function, immunogenicity and/or stability, c) selecting functional polypeptides having altered immunogenicity and/or increased stability, e.g. functional in vivo half-life as compared to the polypeptide of interest, and d) optionally subjecting the nucleotide sequence encoding the polypeptide selected in step c) to one or more repeated cycles of steps a)-c). In a further step the expressed polypeptides of step a) or c) can be conjugated to at least one non-polypeptide moiety.
    Type: Application
    Filed: October 13, 2011
    Publication date: May 3, 2012
    Inventors: Torben Halkier, Anders Hjelholt Pedersen, Jens Sigurd Okkels, Kim Vilbour Andersen
  • Patent number: 8084591
    Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: December 27, 2011
    Assignee: Bayer Healthcare LLC
    Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
  • Publication number: 20110250674
    Abstract: The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of: a. constructing a multiple alignment of at least two amino acid sequences known to have three-dimensional structures similar to endoglucanase V (EGV) from Humicola insolens known from Protein Data Bank entry 4ENG; b. constructing a homology-built three-dimensional structure of the cellulolytic enzyme based on the structure of the EGV; c. identifying amino acid residue positions present in a distance from the substrate binding cleft of not more than 5 ?; d. identifying surface-exposed amino acid residues of the enzyme; e. identifying all charged or potentially charged amino acid residue positions of the enzyme; f. choosing one or more positions wherein the amino acid residue is to be substituted, deleted or where an insertion is to be provided; and g.
    Type: Application
    Filed: June 17, 2011
    Publication date: October 13, 2011
    Applicant: Novozymes A/S
    Inventors: Kim Vilbour Andersen, Martin Schülein, Torben Henriksen, Lars Christiansen, Bo Damgaard, Claus Von der Osten
  • Patent number: 8017372
    Abstract: The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of: a. constructing a multiple alignment of at least two amino acid sequences known to have three-dimensional structures similar to endoglucanase V (EGV) from Humicola insolens known from Protein Data Bank entry 4ENG; b. constructing a homology-built three-dimensional structure of the cellulolytic enzyme based on the structure of the EGV; c. identifying amino acid residue positions present in a distance from the substrate binding cleft of not more than 5 ?; d. identifying surface-exposed amino acid residues of the enzyme; e. identifying all charged or potentially charged amino acid residue positions of the enzyme; f. choosing one or more positions wherein the amino acid residue is to be substituted, deleted or where an insertion is to be provided; and g.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: September 13, 2011
    Assignee: Novozymes A/S
    Inventors: Kim Vilbour Andersen, Martin Schulein, Torben Henriksen, legal representative, Lars Christiansen, Bo Damgaard, Claus Von der Osten
  • Patent number: 7993898
    Abstract: The present invention relates to a method for improving the properties of a cellulolytic enzyme by amino acid substitution, deletion or insertion, the method comprising the steps of: a. constructing a multiple alignment of at least two amino acid sequences known to have three-dimensional structures similar to endoglucanase V (EGV) from Humicola insolens known from Protein Data Bank entry 4ENG; b. constructing a homology-built three-dimensional structure of the cellulolytic enzyme based on the structure of the EGV; c. identifying amino acid residue positions present in a distance from the substrate binding cleft of not more than 5 ?; d. identifying surface-exposed amino acid residues of the enzyme; e. identifying all charged or potentially charged amino acid residue positions of the enzyme; f. choosing one or more positions wherein the amino acid residue is to be substituted, deleted or where an insertion is to be provided; and g.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: August 9, 2011
    Assignee: Novozymes A/S
    Inventors: Kim Vilbour Andersen, Martin Schulein, Torben Henriksen, legal representative, Lars Christensen, Bo Damgaard, Claus Von der Osten